<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701164</url>
  </required_header>
  <id_info>
    <org_study_id>ANX005-GBS-02</org_study_id>
    <nct_id>NCT04701164</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the efficacy and safety of ANX005 administered by&#xD;
      intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome&#xD;
      (GBS). The total duration of study participation is approximately 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GBS Disability Score (GBS-DS)</measure>
    <time_frame>Baseline to Day 56</time_frame>
    <description>Change in GBS-DS in participants recently diagnosed with GBS; scoring is based on a modified functional grading scale administered by a physician as follows: 0 = healthy, 1 = minor symptoms and capable of running, 2 = able to walk 10 meters without assistance but unable to run, 3 = able to walk 10 meters with help, 4 = bedridden, 5 = requires assisted ventilation, and 6 = dead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Number participants recently diagnosed with GBS who experience adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council (MRC) Sum Score</measure>
    <time_frame>Day 8</time_frame>
    <description>Total MRC sum score in which the strength of six muscle groups is evaluated; scores range from 0 = normal to 60 = quadriplegic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Disability Score</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Cumulative disability score as measured by the sum of GBS Disability Score values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation Usage</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Number of days of ventilation usage per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GBS Disability Score (GBS-DS)</measure>
    <time_frame>At Day 29 and Month 6</time_frame>
    <description>GBS Disability Score at Day 29 as an ordinal outcome and at Month 6 as an ordinal outcome for durability of treatment effect.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Guillain-Barre Syndrome</condition>
  <arm_group>
    <arm_group_label>ANX005 Treatment Group - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of ANX005 (Dose 1) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX005 Treatment Group - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of ANX005 (Dose 2) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IV infusion of placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX005</intervention_name>
    <description>Solution for intravenous infusion</description>
    <arm_group_label>ANX005 Treatment Group - Dose 1</arm_group_label>
    <arm_group_label>ANX005 Treatment Group - Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for intravenous infusion</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of GBS according to the National Institute of Neurological Disorders and&#xD;
             Stroke Diagnostic Criteria for Guillain-Barré Syndrome.&#xD;
&#xD;
          -  Onset of GBS-related weakness ≤10 days prior to start of infusion.&#xD;
&#xD;
          -  GBS-DS score of 3,4, or 5 at screening and at Day 1 prior to infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight &gt;150 kg.&#xD;
&#xD;
          -  Unresponsive nerve conduction study results in all nerves tested during screening.&#xD;
&#xD;
          -  Previous or intended, future treatment with either plasma exchange or intravenous&#xD;
             immunoglobulin for GBS.&#xD;
&#xD;
          -  Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's&#xD;
             encephalitis, and overlap syndromes.&#xD;
&#xD;
          -  Prior treatment with any monoclonal antibody.&#xD;
&#xD;
          -  History of hypercoagulable diseases, hyper viscosity, thrombosis, or acute renal&#xD;
             failure.&#xD;
&#xD;
          -  Documented, clinically significant, pre-existing polyneuropathy from another cause.&#xD;
&#xD;
          -  Females who are pregnant, breastfeeding, or unable or unwilling to use 2 methods of&#xD;
             contraception throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Annexon, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>650-822-5500</phone>
    <email>clinicaltrials@annexonbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Neurosciences and Hospital (NINS)</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhahirul Islam, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

